List view / Grid view
Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
For characterising higher order protein structure and accurately defining CQAs of biopharmaceuticals...
This week a new collaborative European project is being launched that aims to re-invigorate the way that research into life sciences and biomedicine is organised and funded. The project, named ORION, will be coordinated by The Centre for Genomic Regulation in Barcelona, Spain, who is one of nine partners taking…
Drug developers sometimes think of imaging as an emerging discipline. But John Waterton, Paul Hockings, Juliana Maynard and Caleb Roberts explain how imaging biomarkers are transforming drug development. Francesco Gatto and Jens Nielsen, from the Chalmers University of Technology in Sweden, discuss moving towards systems biomarkers for cancer diagnosis...
Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Orion and Finland are both celebrating their centenaries in 2017.
The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.
This award recognises outstanding achievements of female researchers in the life sciences in the past five years.
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
GE BioPark Cork, subject to contract and planning approvals, will feature Europe’s first KUBio, prefabricated, off-the-shelf bio-manufacturing facilities...
As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The investment will be used for manufacturing of new respiratory and biopharmaceuticals, to be exported outside the UK to global markets...
Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...
